Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth ...

On Monday, 10 November 2025, the healthcare world was abuzz as two pharmaceutical giants, Pfizer and Novo Nordisk, fiercely ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Wall Street closed sharply higher on Monday, driven by strong rebounds in major artificial intelligence (AI) and technology ...

Wendy’s plans to close hundreds of US restaurants over the next few months in an effort to boost its profit. The Dublin, Ohio ...

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...

The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Pfizer prevails 10B bidding for Metsera, securing a deal to expand its obesity drug portfolio with innovative weight-loss treatments.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...